Published in Nat Cell Biol on October 21, 2012
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A (2013) 2.25
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell (2014) 1.70
ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol (2014) 1.19
Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development (2013) 1.11
Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state. Elife (2014) 1.04
Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev Cell (2014) 1.03
Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res (2014) 0.98
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med (2014) 0.97
RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife (2014) 0.96
Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep (2014) 0.94
PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. Cancer Res (2014) 0.94
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. Mol Cancer (2013) 0.93
Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer. Oncoscience (2013) 0.93
Transcriptional control of cancer metastasis. Trends Cell Biol (2013) 0.92
The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. J Biol Chem (2014) 0.91
Distinctive properties of metastasis-initiating cells. Genes Dev (2016) 0.91
D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells. Mol Cell Endocrinol (2013) 0.89
Regulation of mesenchymal phenotype by MicroRNAs in cancer. Curr Cancer Drug Targets (2013) 0.86
Evaluation of the mechanism of epithelial-mesenchymal transition in human ovarian cancer stem cells transfected with a WW domain-containing oxidoreductase gene. Oncol Lett (2014) 0.86
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol (2016) 0.86
Analysis of the TGFβ-induced program in primary airway epithelial cells shows essential role of NF-κB/RelA signaling network in type II epithelial mesenchymal transition. BMC Genomics (2015) 0.86
Targeting Breast Cancer Metastasis. Breast Cancer (Auckl) (2015) 0.85
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med (2014) 0.84
Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget (2014) 0.84
The mammary cellular hierarchy and breast cancer. Cell Mol Life Sci (2014) 0.84
CPEB1 promotes differentiation and suppresses EMT in mammary epithelial cells. J Cell Sci (2014) 0.83
Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl Med (2014) 0.83
Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse. Adv Exp Med Biol (2015) 0.83
Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. PLoS One (2015) 0.82
p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer (2014) 0.82
Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells. Oncotarget (2016) 0.81
Interplay between PCBP2 and miRNA modulates ARHGDIA expression and function in glioma migration and invasion. Oncotarget (2016) 0.81
Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer. Front Endocrinol (Lausanne) (2015) 0.81
Foxa1 is essential for mammary duct formation. Genesis (2016) 0.80
Bone and cancer: the osteoncology. Clin Cases Miner Bone Metab (2013) 0.80
TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma. Oncotarget (2015) 0.80
Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer. Breast Cancer Res Treat (2016) 0.80
IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res (2014) 0.80
Ovol proteins: guardians against EMT during epithelial differentiation. Dev Cell (2014) 0.79
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS Biol (2015) 0.78
Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein. Oncotarget (2016) 0.78
ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res (2016) 0.77
Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis. Breast Cancer Res (2014) 0.77
Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas. Oncogene (2013) 0.77
Regulation of a TGF-β1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells. Oncogene (2016) 0.77
Paracrine Met signaling triggers epithelial-mesenchymal transition in mammary luminal progenitors, affecting their fate. Elife (2015) 0.76
Setting Snail2's pace during EMT. Nat Cell Biol (2012) 0.76
MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells. PLoS One (2016) 0.75
Metastasis: Elf represses snail. Nat Rev Cancer (2012) 0.75
Gene regulatory network underlying the immortalization of epithelial cells. BMC Syst Biol (2017) 0.75
ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells. Oncol Rep (2017) 0.75
ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation. Cell Death Dis (2016) 0.75
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Biomed Res Int (2017) 0.75
An Atypical System for Studying Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Sci Rep (2016) 0.75
ELF5-Mediated AR Activation Regulates Prostate Cancer Progression. Sci Rep (2017) 0.75
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Epithelial Expression of Human ABO Blood Group Genes Is Dependent upon a Downstream Regulatory Element Functioning through an Epithelial Cell-specific Transcription Factor, Elf5. J Biol Chem (2016) 0.75
Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis. Nat Cell Biol (2017) 0.75
Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication. Pharmacol Ther (2017) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 10.59
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
The ETS-domain transcription factor family. Nat Rev Mol Cell Biol (2001) 6.01
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Molecular biology of the Ets family of transcription factors. Gene (2003) 4.41
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell (2011) 4.08
The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol (2011) 3.80
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol (2005) 3.30
Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer (2007) 3.16
Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem (2011) 2.89
Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell (2008) 2.78
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38
Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res (2011) 2.29
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res (2003) 2.07
The ETS-domain transcription factor family. Int J Biochem Cell Biol (1997) 1.94
A new member of the ETS family fused to EWS in Ewing tumors. Oncogene (1997) 1.79
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73
Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis (1983) 1.67
Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J (2005) 1.52
Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol (2009) 1.49
Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells (2012) 1.37
Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol (2011) 1.34
Ets transcription factors and human disease. Biochim Biophys Acta (1998) 1.30
A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines. Oncogene (1998) 1.27
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res (2006) 1.23
EMT and MET in carcinoma--clinical observations, regulatory pathways and new models. Clin Exp Metastasis (2008) 1.21
Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res (1998) 1.16
ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene (1998) 1.15
Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors. Cancer Genet Cytogenet (1997) 1.01
Dysregulation of developmental pathways in bone metastasis. Bone (2010) 0.99
Reciprocal repression between Sox3 and snail transcription factors defines embryonic territories at gastrulation. Dev Cell (2011) 0.98
Genome-wide search identifies Ccnd2 as a direct transcriptional target of Elf5 in mouse mammary gland. BMC Mol Biol (2010) 0.84
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol (2006) 6.07
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol (2006) 5.09
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol (2013) 3.67
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest (2012) 3.45
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
Homotypic fusion of ER membranes requires the dynamin-like GTPase atlastin. Nature (2009) 3.31
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol (2005) 3.19
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell (2009) 3.15
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics (2012) 2.97
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol (2012) 2.77
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69
Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst (2006) 2.69
A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One (2010) 2.64
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol (2006) 2.38
Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA (2005) 2.31
Managing chronic pain: results from an open-label study using MC5-A Calmare® device. Support Care Cancer (2011) 2.29
Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg (2008) 2.25
Protein binding site prediction using an empirical scoring function. Nucleic Acids Res (2006) 2.19
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 2.10
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. Mol Cell (2002) 2.05
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
ΔNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development (2012) 1.97
Factors that determine academic versus private practice career interest in radiation oncology residents in the United States: results of a nationwide survey. Int J Radiat Oncol Biol Phys (2013) 1.97
Sec1p directly stimulates SNARE-mediated membrane fusion in vitro. J Cell Biol (2004) 1.94
The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res (2009) 1.89
Formation of Tap/NXT1 heterodimers activates Tap-dependent nuclear mRNA export by enhancing recruitment to nuclear pore complexes. Mol Cell Biol (2002) 1.86
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem (2009) 1.81
Waxholm space: an image-based reference for coordinating mouse brain research. Neuroimage (2010) 1.80
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
A knowledge-based energy function for protein-ligand, protein-protein, and protein-DNA complexes. J Med Chem (2005) 1.76
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell (2010) 1.75
An accurate, residue-level, pair potential of mean force for folding and binding based on the distance-scaled, ideal-gas reference state. Protein Sci (2004) 1.74
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res (2002) 1.69
An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One (2009) 1.69
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer (2008) 1.64
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol (2011) 1.60
Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem (2012) 1.58
Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 1.55
Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer (2003) 1.55
Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol (2004) 1.54
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol (2011) 1.54
Accurate and efficient loop selections by the DFIRE-based all-atom statistical potential. Protein Sci (2004) 1.53
ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res (2011) 1.52
Cell fusion as a hidden force in tumor progression. Cancer Res (2009) 1.51
Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer (2011) 1.51
Liposome fusion assay to monitor intracellular membrane fusion machines. Methods Enzymol (2003) 1.49
Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol (2009) 1.49
Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia (2007) 1.49
Structure and transcription of the human m3 muscarinic receptor gene. Am J Respir Cell Mol Biol (2002) 1.47
ACR Appropriateness Criteria® conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast J (2011) 1.47